Long Duration Dual Antiplatelet Treatment Increases Bleeding

This article originally appeared here.
Share this content:
Long Duration Dual Antiplatelet Treatment Increases Bleeding
Long Duration Dual Antiplatelet Treatment Increases Bleeding

WEDNESDAY, Sept. 30, 2015 (HealthDay News) -- Routine use of dual antiplatelet therapy (DAPT) beyond six months after second generation drug-eluting stent (DES) implantation yields mixed clinical results, according to a review published in the October issue of Cardiovascular Therapeutics.

Elsayed Abo-salem, M.D., from the University of Cincinnati, and colleagues conducted a systematic literature search to identify randomized controlled trials (RCTs) comparing the continued use of DAPT with shorter duration of DAPT (aspirin alone) for variable durations beyond three months after DES implantation.

The researchers identified 10 RCTs with 32,136 subjects randomized to continued use of DAPT versus aspirin alone for variable durations after three months of DES implantation. The studies were not significant heterogeneously. Longer DAPT resulted in a significant reduction in stent thrombosis (P < 0.01) and myocardial infarction (P < 0.01), and a significant increase in major bleeding (P < 0.01), compared to shorter DAPT. Cardiac deaths or stroke did not differ by DAPT length. With shorter DAPT, all-cause deaths were slightly lower, compared to longer DAPT (odds ratio, 0.8; P = 0.04).

"DAPT continued beyond six months after second generation DES implantation decreases stent thrombosis and myocardial infarction, but increases major bleeding and all-causes mortality compared to shorter DAPT (aspirin alone)," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »